Comparison of the inhibitory effect of different doses of subconjunctival bevacizumab application in an experimental model of corneal neovascularization

● AIM: To evaluate the inhibitory effect of subconjunctival bevacizumab as single-and multiple-dose application, and compare their effects on corneal neovascularization in a rat model.● METHODS: Thirty adult Sprague-Dawley rats were used in this experimental study. The central cornea of the rats was cauterized chemically. The rats were randomly enrolled into three groups. All groups received subconjunctival injections. In Group 1(control group, n=10), 0.05 m L 0.9% Na Cl solution was injected on the first day. In Group 2(single-dose group, n=10), 0.05 m L bevacizumab(1.25 mg) was injected on the first day. In Group 3(multiple-dose group, n=10), four doses of 0.05 m L bevacizumab(1.25 mg) were injected on the first, third, fifth and seventh day. Slit-lamp examination of all rats was performed at the third and ninth day. Digital images of the corneas were taken and analyzed using image analysis software to calculate corneal neovascularization area. All rats were sacrificed on the tenth day. In corneal sections, the number of blood vessels, state of inflammation and collagen formation was evaluated histopathologically.● RESULTS: In Group 3, corneal edema grades were significantly lower than Group 1 and Group 2(P=0.02, and P=0.035, respectively). The mean percentage of neovascularized corneal area in Group 3 was significantly lower than Group 2(P=0.005). On histopathological examination, Group 2 and Group 3 showed significantly less number of blood vessels than Group 1(P=0.005, and P=0.001, respectively). Additionally, Group 3 showed significantly less number of blood vessels compared to Group 2(P=0.019). Inflammation and edema grades were significantly lower in Group 3 compared to Group 1(P=0.001).● CONCLUSION: Subconjunctival bevacizumab injection is effective in inhibition of newly formed corneal neovascularization. The multiple-dose bevacizumab treatment seems to be more effective compared to single-dose treatment.